What does ELDN's zero EPS in Q3 2023 indicate?

Eldon Pharmaceuticals (ELDN) reported a zero EPS in Q3 2023, which indicates that the company's earnings per share for that quarter were not impacted by any significant losses or gains. This result suggests that ELDN's financial performance was stable during that period, with no major factors contributing to either positive or negative earnings. However, a negative EPS of -$0.33 in the previous quarter suggests that the company may have had some challenges or expenses that affected its profitability, but these issues did not lead to a further deterioration of its financial performance in Q3 2023. Overall, a zero EPS indicates a period of relative stability and profitability for ELDN.